Home

About Us

Research

The Team

In the News

Contact Us

Home

Absynth was formed in 2007 from the University of Sheffield and is developing vaccines and antibodies to treat bacterial infections.  The company’s distinctive approach uses genomics to identify highly conserved bacterial protein targets, essential for life and capable of stimulating the immune system. Absynth’s  lead programme focuses on infections  caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).

The company was founded using an initial investment of £325,000 from Biofusion plc, now Fusion IP (www.fusionip.co.uk)  and is producing lead vaccine and therapeutic antibody candidates for entry into clinical trials.

Hospital acquired infections are an increasing public health concern and are responsible for a rise in the number of hospital deaths.

These infections are caused by micro-organisms including MRSA. Absynth’s technology will be used to develop an MSRA vaccine and antibodies to treat significant MRSA infections as well as in other applications.

For further information, please browse this website or e-mail us at fiona.marston@absynthbiologics.co.uk